Mental imagery with self-regulation to help daily activities in Parkinson's disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This interventional study compares three approaches for people with Parkinson’s disease: mental imagery with self-regulation, conventional learning, and exercise. Participants complete six weeks of the assigned program and then undergo assessments of daily activities, overall function, cognition, and motor skills. The goal is to see if mental imagery with self-regulation can improve daily task performance and related functions more effectively or durably than traditional rehabilitation strategies. The trial builds on prior work suggesting cueing and imagery can benefit task performance by addressing cognitive and attentional aspects of movement in Parkinson’s disease. Eligibility requires a clinician-confirmed Parkinson’s diagnosis, mild-to-moderate disease in the ON state, intact attention and memory, and no significant depression.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. have been diagnosed with Parkinson's disease by a neurologist according to the diagnostic criteria of the UK Parkinson's Disease Society Brain Bank, regardless of their age range;
2. have Parkinson's disease with mild-to-moderate severity determined in the 'ON' phase, with scores of 1 to 3 on the Hoehn and Yahr scale;
3. have been screened for intact attention and short-term memory functions by repeating all five words in the 'memory' question and scoring '1' (full marks) in forward order repeat in the 'read list of digits' in the 'attention' question of the Montreal Cognitive Assessment; and
4. do not have depression, as indicated by scores less than 2 on the 4-item Geriatric Depression Scale

Exclusion Criteria:

1. severe dyskinesia or severe ON-OFF motor fluctuations;
2. stereotaxic brain surgery for Parkinson's disease;
3. changes in dopamine therapy dose within 3 months before the study starts;
4. disabling comorbidities such as cognitive disorders including stroke and depression; and
5. language difficulties, unstable cardia or reparatory illness, or other medical conditions that may affect participation.

Where it's running

• The Hong Kong Polytechnic University
  Hong Kong, Hong Kong Recruiting

Study contacts

• Study coordinator: Karen P. Y. Liu
• Email: karen.liu@polyu.edu.hk
• Phone: 852 27665386

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ginger as a Modifier of Ghrelin Levels in Parkinson’s Disease and REM Sleep Behavior Disorder

  This study tests whether ginger capsules can raise ghrelin levels in people with Parkinson’s disease, REM sleep behavior disorder, and healthy controls.

  Recruiting Cambridge University Hospitals NHS Foundation Trust · Cambridge · NCT07882108

• Intraoperative Microelectrode Recordings with MAVEN vs Standard Equipment

  This study tests whether MAVEN can match the recording data collected during DBS surgery for movement disorders using standard equipment.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07868614

• Real-world experiences of Inbrija for Parkinson's OFF episodes

  This study looks at how people with Parkinson’s who use Inbrija for OFF episodes feel and function in daily life.

  Recruiting Merz Pharmaceuticals GmbH · Altmünster and 1 other locations · NCT07797790

• Gut methane and Parkinson's: measuring if a probiotic helps people with Parkinson's, REM sleep behavior disorder, or cognitive concerns

  This study tests whether a probiotic containing Limosilactobacillus reuteri can help people with Parkinson's disease, those at high risk for PD, and related cognitive issues by potentially improving gut methane levels and overall symptoms.

  Recruiting University of Cambridge · Cambridge, CB2 · NCT07786116

• Test of RO7568282 in early Parkinson's disease

  This study tests whether RO7568282, compared with placebo, is safe and helps people with early Parkinson's disease who are already taking levodopa.

  Recruiting at 4 sites Phase 2 Hoffmann-La Roche · Boca Raton, Florida and 3 other locations · NCT07781644

• TRB-001 vaccination in Parkinson's disease: safety and biological effects in a small, single-arm study

  This pilot trial tests TRB-001 vaccination in adults with Parkinson's who previously had active aSyn immunotherapy to see if it is safe and tolerable and to explore immune responses and biological effects.

  Recruiting Phase 1 Tridem Bioscience FlexCo · Vienna · NCT07777484

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.